Biogen Inc. – NASDAQ:BIIB

Add to watchlist

$138.75

-12.56

-8.3%

Market closed

Open in 1 day

-34.23%

month

-34.23%

quarter

-42.23%

year

Market Cap	21.78B
Enterprise value	44.15B

P/E	13.46
EV/Sales	4.34
EV/EBITDA	10.05
Price/Sales	4.02
Price/Book	3.05
PEG ratio	0.14
EPS	8.05

Revenue	9.57B
EBITDA	2.39B
Income	1.16B
Revenue Q/Q	-10.66%
Revenue Y/Y	-5.26%

Profit margin	29.95%
Oper. margin	28.96%
Gross margin	77.61%
EBIT margin	28.96%
EBITDA margin	25.03%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Biogen Stock Forecast

M Q Y

Last Year

$242.33

Potential upside: 74.65%

Analysts Price target
Financials & Ratios estimates

Biogen Inc. (NASDAQ:BIIB): Profit margin
Jun 2023	2.45B	591.6M	24.09%
Sep 2023	2.53B	-68.1M	-2.69%
Dec 2023	2.38B	249.7M	10.46%
Mar 2024	2.20B	393.4M	17.88%

Biogen Inc. (NASDAQ:BIIB): Debt to assets
Jun 2023	25156800000	10.69B	42.52%
Sep 2023	28193200000	13.71B	48.64%
Dec 2023	26844800000	12.04B	44.87%
Mar 2024	26567600000	11.35B	42.74%

Biogen Inc. (NASDAQ:BIIB): Cash Flow
Jun 2023	487M	-753.5M	-9.8M
Sep 2023	592.4M	-1.74B	848.6M
Dec 2023	12.5M	-652.3M	-646.1M
Mar 2024	553.2M	-66M	-439.6M

Biogen alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Google Trends

Biogen Area of Focus

Biogen Inc. (NASDAQ:BIIB): Google Trends - Biogen Area of Focus
13 Aug 2023	44	15	3
20 Aug 2023	43	14	3
27 Aug 2023	45	15	3
3 Sep 2023	42	14	3
10 Sep 2023	48	16	3
17 Sep 2023	47	16	4
24 Sep 2023	52	18	4
1 Oct 2023	47	17	3
8 Oct 2023	46	16	3
15 Oct 2023	46	16	4
22 Oct 2023	47	15	3
29 Oct 2023	47	15	3
5 Nov 2023	50	16	3
12 Nov 2023	39	16	3
19 Nov 2023	43	18	3
26 Nov 2023	54	16	3
3 Dec 2023	45	14	3
10 Dec 2023	47	14	3
17 Dec 2023	46	16	3
24 Dec 2023	42	14	3

Biogen Products

Biogen Inc. (NASDAQ:BIIB): Google Trends - Biogen Products
19 Feb 2023	15	6	40	45
26 Feb 2023	20	16	43	37
5 Mar 2023	18	6	44	49
12 Mar 2023	22	9	39	32
19 Mar 2023	25	11	42	36
26 Mar 2023	23	9	43	35
2 Apr 2023	23	12	42	39
9 Apr 2023	31	13	45	45
16 Apr 2023	25	9	39	38
23 Apr 2023	21	10	39	30
30 Apr 2023	16	9	48	54
7 May 2023	22	13	39	31
14 May 2023	22	9	33	28
21 May 2023	15	8	36	27
28 May 2023	21	9	47	37
4 Jun 2023	20	8	39	41
11 Jun 2023	19	12	27	34
18 Jun 2023	19	0	41	32
25 Jun 2023	22	4	38	39
2 Jul 2023	22	18	37	31

Numbers represent search interest relative to the highest point on the chart for the given region and time.

A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.

Biogen Inc. (NASDAQ:BIIB): Job openings
Aug 2023	122
Sep 2023	103
Oct 2023	114
Nov 2023	143
Dec 2023	169
Jan 2024	175
Feb 2024	188
Apr 2024	236
May 2024	252
Jun 2024	222
Jul 2024	235
Dec 2024	170

Biogen
Employees

Biogen Inc. (NASDAQ:BIIB): Employee count
Aug 2023	8,725
Sep 2023	8,725
Oct 2023	8,725
Nov 2023	8,725
Dec 2023	8,725
Jan 2024	8,725
Feb 2024	8,725
Mar 2024	7,570
Apr 2024	7,570
May 2024	7,570
Jun 2024	7,570
Jul 2024	7,570

Biogen
Hedge Funds Holdings Q1 2022

80.66% -2.17%

of BIIB is owned by hedge funds

915 -65

hedge funds hold BIIB stock

120.66M -2.41M

shares is hold by hedge funds

BIIB hedge funds holdings changes

Biogen Inc. (NASDAQ:BIIB): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	455	789
Apr 2024	0	93
Sep 2024	0	431
Dec 2024	0	110

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	9 Dec 2024	SINGHAL PRIYA officer: Head of Development officer: Head of Development	Common Stock	110	$157.21	$17,293
Option	6 Dec 2024	SINGHAL PRIYA officer: Head of Development officer: Head of Development	Common Stock	426	N/A	N/A
Option	6 Dec 2024	SINGHAL PRIYA officer: Head of Development officer: Head of Development	Restricted Stock Unit	426	N/A	N/A
Option	6 Dec 2024	KRAMER ROBIN officer: Chief Accounting Officer officer: Chief Accounting Officer	Common Stock	351	N/A	N/A
Option	6 Dec 2024	KRAMER ROBIN officer: Chief Accounting Officer officer: Chief Accounting Officer	Restricted Stock Unit	351	N/A	N/A
Option	1 Nov 2024	GROGAN JANE officer: Head of Research officer: Head of Research	Restricted Stock Unit	695	N/A	N/A
Option	1 Nov 2024	GROGAN JANE officer: Head of Research officer: Head of Research	Common Stock	695	N/A	N/A
Sale	3 Sep 2024	SINGHAL PRIYA officer: Head of Development officer: Head of Development	Common Stock	431	$204.22	$88,019
Option	30 Aug 2024	SINGHAL PRIYA officer: Head of Development officer: Head of Development	Common Stock	1,668	N/A	N/A
Option	30 Aug 2024	SINGHAL PRIYA officer: Head of Development officer: Head of Development	Restricted Stock Unit	1,668	N/A	N/A

Biogen
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 24 Apr 2024	Q1 2024 Earnings Call Transcript
Q4 2023 13 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 8 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 25 Jul 2023	Q2 2023 Earnings Call Transcript

BIIB earnings call transcripts

Biogen
Executives

Insider	Age	Compensation
Mr. Michel Vounatsos (1962) Chief Executive Officer & Director	63	$4,510,000
Ms. Susan H. Alexander (1957) Executive Vice President, Chief Legal Officer & Sec.	68	$1,580,000
Mr. Michael R. McDonnell (1964) Executive Vice President & Chief Financial Officer	61	$1,560,000
Mr. Chirfi Guindo (1966) Executive Vice President of Global Product Strategy & Commercialization	59	$1,170,000

Biogen
Latest News

Monday, 23 December 2024
15:45	Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman	youtube.com
Thursday, 12 December 2024
12:52	Private Medicare plans must cover Biogen's ALS drug, US agency says	reuters.com
Wednesday, 11 December 2024
08:00	Analysts Predict These Will Be Next Year's Top 10 Stocks	investors.com
Tuesday, 10 December 2024
09:35	Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock	zacks.com
Monday, 9 December 2024
13:44	Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown	benzinga.com
Tuesday, 3 December 2024
12:15	Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript	seekingalpha.com
09:57	Biogen expects steady growth for Alzheimer's drug Leqembi in near term	reuters.com
Tuesday, 26 November 2024
07:30	These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over	fool.com
Wednesday, 20 November 2024
13:32	Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside	benzinga.com
Tuesday, 19 November 2024
01:00	Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity	globenewswire.com
Monday, 18 November 2024
13:18	Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026	benzinga.com
07:00	Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™	globenewswire.com
Friday, 15 November 2024
10:05	Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe	zacks.com
Thursday, 14 November 2024
13:21	Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug	marketwatch.com
11:23	Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease	globenewswire.com
11:17	EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen	reuters.com
Wednesday, 13 November 2024
16:13	Biogen initiated with a Neutral at Citi	https://thefly.com
Tuesday, 12 November 2024
10:46	Here's Why Biogen Inc. (BIIB) is a Strong Value Stock	zacks.com
Wednesday, 6 November 2024
12:45	BIIB vs. MYGN: Which Stock Is the Better Value Option?	zacks.com
Tuesday, 5 November 2024
10:45	Are Investors Undervaluing Biogen (BIIB) Right Now?	zacks.com
Monday, 4 November 2024
10:35	Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner	zacks.com
Thursday, 31 October 2024
17:42	Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter	seekingalpha.com
13:28	Biogen Analysts Slash Their Forecasts After Q3 Results	benzinga.com
Wednesday, 30 October 2024
19:30	Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference	globenewswire.com
15:06	Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View	zacks.com
12:49	Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript	seekingalpha.com
10:36	Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say	zacks.com
09:06	Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates	zacks.com
07:47	Biogen's stock pops after earnings top estimates and company raises guidance	marketwatch.com
06:54	Biogen lifts annual profit forecast as cost cuts help	reuters.com

Ideas & Opinions

Seeking Alpha 21 Jul 2025

Eli Lilly: Competition Melts Away
Seeking Alpha 13 Jul 2025

Why Novartis Is Still A 'Buy' After 15% Surge
Seeking Alpha 23 Jun 2025

Biogen: Investors Are Missing The Bigger Picture
Seeking Alpha 16 May 2025

Does Anavex's Alzheimer's Drug Actually Confer Benefit Over Three Years?
Seeking Alpha 12 May 2025

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Seeking Alpha 5 May 2025

Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement
Seeking Alpha 9 Apr 2025

Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag
Seeking Alpha 21 Jan 2025

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
Seeking Alpha 19 Jan 2025

Top 4 Immunology Stocks Poised For Growth In 2025
Seeking Alpha 12 Jan 2025

Playing The Odds Of Anavex Alzheimer's Drug Approval

Frequently Asked Questions (FAQ)

What's the price of Biogen stock today?

One share of Biogen stock can currently be purchased for approximately $138.75.
When is Biogen's next earnings date?

Unfortunately, Biogen's (BIIB) next earnings date is currently unknown.
Does Biogen pay dividends?

No, Biogen does not pay dividends.
How much money does Biogen make?

Biogen has a market capitalization of 21.78B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 3.32% to 9.84B US dollars.
What is Biogen's stock symbol?

Biogen Inc. is traded on the NASDAQ under the ticker symbol "BIIB".
What is Biogen's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - General industry.
How do i buy shares of Biogen?

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Biogen's key executives?
Biogen's management team includes the following people:
- Mr. Michel Vounatsos Chief Executive Officer & Director(age: 63, pay: $4,510,000)
- Ms. Susan H. Alexander Executive Vice President, Chief Legal Officer & Sec.(age: 68, pay: $1,580,000)
- Mr. Michael R. McDonnell Executive Vice President & Chief Financial Officer(age: 61, pay: $1,560,000)
- Mr. Chirfi Guindo Executive Vice President of Global Product Strategy & Commercialization(age: 59, pay: $1,170,000)
How many employees does Biogen have?

As Jul 2024, Biogen employs 7,570 workers.
When Biogen went public?

Biogen Inc. is publicly traded company for more then 33 years since IPO on 17 Sep 1991.
What is Biogen's official website?

The official website for Biogen is biogen.com.
Where are Biogen's headquarters?

Biogen is headquartered at 225 Binney Street, Cambridge, MA.
How can i contact Biogen?

Biogen's mailing address is 225 Binney Street, Cambridge, MA and company can be reached via phone at +61 76792000.
What is Biogen stock forecast & price target?

Based on 9 Wall Street analysts` predicted price targets for Biogen in the last 12 months, the avarage price target is $242.33. The average price target represents a 74.65% change from the last price of $138.75.

Biogen Inc.

biogen.com

Exchange:

NASDAQ

Full time employees:

7,570

Industry:

Drug Manufacturers - General

Sector:

Healthcare

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

+61 76792000

225 Binney Street
Cambridge, MA 02142

CIK: 0000875045
ISIN: US09062X1037
CUSIP: 09062X103